We’re still a bit of a ways off from a coronavirus vaccine, but the first Phase 3 trial in the US is expected to begin Tuesday.
The vaccine candidate — developed by the Vaccine Research Center at the National Institutes of Health’s National Institute of Allergy and Infectious Diseases, in partnership with the biotechnology company Moderna — is expected to be tested on 30,000 volunteers. Early results from the Phase 1 study were published in the New England Journal of Medicine in mid-July. The study showed that the vaccine, given at three different doses, triggered an immune response in the people who received it.
You can read this fascinating conversation between CNN’s Sanjay Gupta and Dr. Barney Graham, the deputy director of the Vaccine Research Center, for more on how the Moderna vaccine works.